Fig. 3

Study protocol. Patients were given goserelin once every 4 weeks for 24 weeks. hCG was administrated with a dose of 2000 IU for once a week for 20 weeks. hMG was injected at a dose of 150 IU for twice a week for 16 weeks. Twenty four weeks later, all patients received the secondary TESE. Plasma hormone analysis was performed at the first TESE, week 4, week 8 and week 24 of the treatment